Germany In-Vitro Diagnostics Market - Growth, Trends, and Forecast (2020 - 2025)

The market is segmented by Test Type, Product (Instrument, Reagent, Others), Usability, Application, End-User and Geography

Market Snapshot

Study Period:

2016-2024

Base Year:

2019

Major Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

The IVD market in Germany is the largest in Europe. It involves development and manufacture of biological and chemical reagents, test kits, automated machines, and devices that are used to analyze body fluids. Most of the sector comprises of small and medium sized enterprises (SMEs). According to the German Diagnostics Industry Association (VDGH), the IVD and reagent market turnover recorded in 2016 amounted to roughly EUR 2-3 billion. Companies generated the bulk of their turnover with the reagents (86.5% of turnover). Instruments and services totaled 13.5% of turnover.  Innovative developments in the IVD field are currently driven by four major trends: point-of-care testing, automation, digitalization, and the concept of personalize medicine. Some other factors contributing to the growth of market include rapid increase in the chronic and infectious disease population, technological advances, rapidly aging population, and advent of point of care diagnostics.  Some of the factors limiting the growth of the market are a lack of proper reimbursement policies and cumbersome regulatory framework.

Scope of the Report

As per the scope of the Germany In-Vitro Diagnostics market includes medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as Diabetes and Cancer.

Technique
Clinical Chemistry
Molecular Diagnostics
Hematology
Immuno Diagnostics
Other Techniques
Product
Instrument
Reagent
Others
Usability
Disposable IVD Devices
Reusable IVD Devices
Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Other Applications
End Users
Diagnostic Laboratories
Hospitals & Clinics
Other End Users

Report scope can be customized per your requirements. Click here.

Key Market Trends

Molecular diagnostic segment dominates the Germany In-Vitro Diagnostics Market

Molecular diagnostics are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. On the basis of technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetics, and molecular imaging. Molecular diagnostics has emerged as one of the largest and fastest growing sectors of the IVD industry in Germany. This development is fueled by the introduction of powerful techniques, such as real-time polymerase chain reaction (PCR) and next generation sequencing (NGS), which allow the amplification and decoding of genetic and epigenetic information. 

To understand key trends, Download Sample Report

Competitive Landscape

Germany In-Vitro Diagnostics market has rapidly evolved over the last few years. Industry observed significant changes in adoting market strategies such as product developments, mergers and acquisitions in recent years. Thus, the Germany In-Vitro Diagnostics market has become a very competitive industry. Major companies in the market are Thermo Fischer Scientific Inc., Qiagen N.V., Abbott Laboratories, Siemens Healthcare GmbH and F. Hoffmann-La Roche AG among others

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rapid Increase in Chronic Diseases

      2. 4.2.2 Increasing Number of Private Hospitals and Independent Testing Laboratories

      3. 4.2.3 Increasing Demand for Point-of-Care Testing and Personalized Medicine

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulations

      2. 4.3.2 Cumbersome Reimbursement Procedures

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Technique

      1. 5.1.1 Clinical Chemistry

      2. 5.1.2 Molecular Diagnostics

      3. 5.1.3 Hematology

      4. 5.1.4 Immuno Diagnostics

      5. 5.1.5 Other Techniques

    2. 5.2 Product

      1. 5.2.1 Instrument

      2. 5.2.2 Reagent

      3. 5.2.3 Others

    3. 5.3 Usability

      1. 5.3.1 Disposable IVD Devices

      2. 5.3.2 Reusable IVD Devices

    4. 5.4 Application

      1. 5.4.1 Infectious Disease

      2. 5.4.2 Diabetes

      3. 5.4.3 Cancer/Oncology

      4. 5.4.4 Cardiology

      5. 5.4.5 Autoimmune Disease

      6. 5.4.6 Nephrology

      7. 5.4.7 Other Applications

    5. 5.5 End Users

      1. 5.5.1 Diagnostic Laboratories

      2. 5.5.2 Hospitals & Clinics

      3. 5.5.3 Other End Users

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Becton, Dickinson and Company

      3. 6.1.3 Bio-Rad Laboratories Inc.

      4. 6.1.4 bioMerieux SA

      5. 6.1.5 Danaher Corporation

      6. 6.1.6 Epigenomics Inc.

      7. 6.1.7 F. Hoffmann-La Roche AG

      8. 6.1.8 Johnson & Johnson

      9. 6.1.9 Qiagen N.V.

      10. 6.1.10 Siemens Healthcare GmbH

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

Related Reports